Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Update on FDA Warning Letter

DETROIT, Nov. 21 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Alternext US: CPD) announced today that it will be filing its response to the FDA warning letter on November 24, 2008 as planned. In the warning letter, received on October 31, 2008, the FDA requested a response from Caraco within 15 business days, ending November 24, 2008.

As previously disclosed, the warning letter was issued as a follow up to the last FDA inspection of the Company's manufacturing facility in Detroit, Michigan which was initiated in May 2008. Until the Company's responses to the observations have been clarified and explanations provided to the satisfaction of the FDA, the FDA may in the near term withhold approval of pending new drug applications listing the facility as the manufacturer. The Company's sales of current products continue in the normal course of business.

The Company is committed to working cooperatively and expeditiously with the FDA to resolve the matters indicated in its letter.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Item 1A to the Corporation's annual report on Form 10-K, and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
2. Caraco Pharmaceutical Laboratories, Ltd. Reaches Agreement with Labor Union
3. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
5. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
6. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
7. Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
8. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
9. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
Post Your Comments:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... According to ... a recent study has shown that women who successfully lose weight with a bariatric ... the United States each year. The article notes that anywhere from 40 to 50 ...
(Date:10/13/2015)... ... 13, 2015 , ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to ... be held March 2nd and 3rd, 2016. The annual meeting, along with the ... physicians from around the world. , Key topics at this year's event will include ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... unique private messaging application, announced today a significant contract that will provide its ... Independence plans to build on the growing success of its Relay program, IBX ...
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the launch of ... train with, participate in local fitness & sporting events, and stay motivated. ... high medical costs drive us to get more serious about fitness and wellness, individuals ...
(Date:10/13/2015)... MA (PRWEB) , ... October 13, 2015 , ... Protein ... of the body, including muscle, bone, and blood. But how much protein does the ... complicated than it might seem, according to the October 2015 issue of Harvard ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)...  A minimally-invasive treatment just became available to men ... more than 10 years of clinical trials, the Food ... of High Intensity Focused Ultrasound (HIFU), a procedure that ... tissue and minimizing chances for erectile and urinary dysfunction ... a pioneering Miami urologist who ...
(Date:10/13/2015)... ALEXANDRIA, Va. , Oct. 13, 2015 /PRNewswire-USNewswire/ ... Pharmacists Association,s (NCPA) Digest , sponsored by ... to prescription medication and more diversified pharmacy revenue ... independent community pharmacies. NCPA Digest ... to patients and particularly those in underserved inner ...
(Date:10/13/2015)... , Oct. 13, 2015  Human Longevity, Inc. ... practice of medicine, announced today the launch of the ... project that has the potential to transform healthcare. The ... Diego, CA , at HLI,s headquarters facility. More ... in other US and International cities. ...
Breaking Medicine Technology: